Lisi's points about the 2 newly approved indications for the use of troglitazone and the role heterogeneity has on the effects of β-adrenergic blocking agents on serum lipoprotein levels are well taken. It must be noted that the latter concept is based on limited data and that the adverse effects of β-adrenergic blocking agents on lipoprotein fractions may be only ameliorated and not completely prevented by substituting agents with intrinsic sympathomimetic activity.1,2 It is true that use of a combined α- and β-adrenergic blocking agent tends to be associated with neutral lipid effects; however, decreases in high-density lipoprotein cholesterol levels have frequently been reported.3-5
Dagogo-Jack S. Troglitazone: Monotherapy Indication. Arch Intern Med. 1998;158(4):412. doi:https://doi.org/
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: